ClinicalTrials.Veeva

Menu
S

Sharp HealthCare | Sharp Center for Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Docetaxel
Gemcitabine
Prednisone
Milvexian
MCLA-158
Sacituzumab
Enobosarm
Ompenaclid
Platinum
RCHOP

Parent organization

This site is a part of Sharp HealthCare

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 29 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Active, not recruiting
Myelofibrosis
Drug: Imetelstat
Drug: Best Available Therapy (BAT)

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (R...

Enrolling
Esophageal Cancer
Gastric Cancer
Combination Product: MCLA-158 + FOLFOX
Combination Product: MCLA-158 + FOLFIRI
Locations recently updated

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the...

Enrolling
Prostatic Neoplasms, Castration-Resistant
Drug: Docetaxel
Drug: Prednisone

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting
Solid Tumor
Malignant Neoplasm
Drug: nab-sirolimus

Trial sponsors

S
C
D
Janssen (J&J Innovative Medicine) logo
Seagen logo
A
C
D
Genentech logo
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems